NCT06756100 Early Inflammatory Bowel Disease Progression
| NCT ID | NCT06756100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Condition | Inflammatory Bowel Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2023-07-07 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2023-07-07 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the capacity of the gut microbial composition and function to predict the course of IBD during the first year after diagnosis.
Eligibility Criteria
Inclusion Criteria: * Adult patients with with at least 3 weeks of gastrointestinal symptoms including diarrhea, rectal bleeding, abdominal pain, tenesmus or urgency Exclusion Criteria: * Confirmed infectious disease of the gastrointestinal tract
Contact & Investigator
Cristian Hernández-Rocha, MD
PRINCIPAL INVESTIGATOR
Pontificia Universidad Catolica of chile
Frequently Asked Questions
Who can join the NCT06756100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06756100 currently recruiting?
Yes, NCT06756100 is actively recruiting participants. Contact the research team at caherna4@uc.cl for enrollment information.
Where is the NCT06756100 trial being conducted?
This trial is being conducted at Santiago, Chile.
Who is sponsoring the NCT06756100 clinical trial?
NCT06756100 is sponsored by Pontificia Universidad Catolica de Chile. The principal investigator is Cristian Hernández-Rocha, MD at Pontificia Universidad Catolica of chile. The trial plans to enroll 140 participants.